Indegene Ltd. offers digital solutions to the life sciences industry, aiding in drug development, clinical trials, regulatory submissions, and marketing. Despite not issuing dividends recently, the company shows robust financial growth, with a projected FY PAT of 321 Cr. and a fivefold increase in total assets since FY21. Revenue has also risen to Rs. 2625 Cr. in FY24. Indegene's digital focus and specialized services give it a virtual monopoly in its field, leading to consistent growth. While the current valuation may seem high, its unique position suggests it's a reasonable investment. With bright prospects ahead in the life sciences sector, investors may find this IPO appealing for medium to long-term rewards.